Journal article
A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia
Abstract
Background: Based on evidence of activity in epithelial tumors in preclinical and Phase I studies, its novel mechanism of action, and its tolerability we undertook a study of bortezomib [PS-341], a reversible proteasome inhibitor, for patients with advanced or metastatic urothelial cancer.Patients and methods: Patients with advanced or metastatic unresectable urothelial carcinoma were enrolled onto this multicenter, phase II trial. Patients …
Authors
Gomez-Abuin G; Winquist E; Stadler WM; Pond G; Degendorfer P; Wright J; Moore MJ
Journal
Investigational New Drugs, Vol. 25, No. 2, pp. 181–185
Publisher
Springer Nature
Publication Date
April 2007
DOI
10.1007/s10637-006-9009-4
ISSN
0167-6997